STOCK TITAN
  1. Home
  2. Sec-filings
  3. ALGS
  4. [Form 4] Aligos Therapeutics, Inc. Insider Trading Activity

[Form 4] Aligos Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock ALGS logo
Aligos Therapeutics, Inc.

NASDAQ:ALGS

ALGS Rankings

#5144 Ranked by Market Cap
N/A Ranked by Dividends

ALGS Latest News

Sep 3, 2025
Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting
Sep 2, 2025
Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Aug 20, 2025
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs
Aug 15, 2025
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 13, 2025
Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection

ALGS Latest SEC Filings

Aug 14, 2025
[SCHEDULE 13G/A] Aligos Therapeutics, Inc. SEC Filing
Aug 13, 2025
[SCHEDULE 13G] Aligos Therapeutics, Inc. SEC Filing
Aug 12, 2025
[SCHEDULE 13G/A] Aligos Therapeutics, Inc. SEC Filing
Aug 6, 2025
[S-8] Aligos Therapeutics, Inc. Employee Benefit Plan Registration
Aug 6, 2025
[10-Q] Aligos Therapeutics, Inc. Quarterly Earnings Report

ALGS Stock Data

71.18M
4.80M
10.37%
54.15%
4.49%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO